Literature DB >> 20007244

beta2-integrins in demyelinating disease: not adhering to the paradigm.

Xianzhen Hu1, Jillian E Wohler, Kari J Dugger, Scott R Barnum.   

Abstract

The beta(2)-integrins are a subfamily of integrins expressed on leukocytes that play an essential role in leukocyte trafficking, activation, and many other functions. Studies in EAE, the animal model for multiple sclerosis, show differential requirements for beta(2)-integrins in this disease model, ranging from critical in the case of LFA-1 (CD11a/CD18) to unimportant in the case of CD11d/CD18. Importantly, expression of beta(2)-integrins on T cell subsets provides some clues as to the function(s) these adhesion molecules play in disease development. For example, transferred EAE studies have shown that Mac-1 (CD11b/CD18) expression on alphabeta T cells is critical for disease development, and the absence of LFA-1 on Tregs in recipient mice results in exacerbated disease. In this review, we summarize recent findings regarding the role of beta(2)-integrins in demyelinating disease and new information about the role of beta(2)-integrins with respect to alterations in Treg numbers and function. In addition, we discuss the potential for targeting beta(2)-integrins in human demyelinating disease in light of the recent animal model studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20007244      PMCID: PMC3212424          DOI: 10.1189/jlb.1009654

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  67 in total

1.  Structural and functional characterization of the leukocyte integrin gene CD11d. Essential role of Sp1 and Sp3.

Authors:  J D Noti; A K Johnson; J D Dillon
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

Review 2.  T-cell function and migration. Two sides of the same coin.

Authors:  U H von Andrian; C R Mackay
Journal:  N Engl J Med       Date:  2000-10-05       Impact factor: 91.245

Review 3.  New insights into the structural basis of integrin activation.

Authors:  Jian-Ping Xiong; Thilo Stehle; Simon L Goodman; M Amin Arnaout
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

4.  Differential regulatory capacity of CD25+ T regulatory cells and preactivated CD25+ T regulatory cells on development, functional activation, and proliferation of Th2 cells.

Authors:  Michael Stassen; Helmut Jonuleit; Christian Müller; Matthias Klein; Christoph Richter; Tobias Bopp; Steffen Schmitt; Edgar Schmitt
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

5.  Transient blockade of the CD11d/CD18 integrin reduces secondary damage after spinal cord injury, improving sensory, autonomic, and motor function.

Authors:  Denis Gris; Daniel R Marsh; Mark A Oatway; Yuhua Chen; Eilis F Hamilton; Gregory A Dekaban; Lynne C Weaver
Journal:  J Neurosci       Date:  2004-04-21       Impact factor: 6.167

Review 6.  Integrins: bidirectional, allosteric signaling machines.

Authors:  Richard O Hynes
Journal:  Cell       Date:  2002-09-20       Impact factor: 41.582

Review 7.  Immunoglobulins treatment in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  A Achiron; S Miron
Journal:  Mult Scler       Date:  2000-10       Impact factor: 6.312

8.  Inhibition of monocyte/macrophage migration to a spinal cord injury site by an antibody to the integrin alphaD: a potential new anti-inflammatory treatment.

Authors:  P J Mabon; L C Weaver; G A Dekaban
Journal:  Exp Neurol       Date:  2000-11       Impact factor: 5.330

9.  CD4+ CD25+ regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo.

Authors:  Guillaume Oldenhove; Magali de Heusch; Georgette Urbain-Vansanten; Jacques Urbain; Charlie Maliszewski; Oberdan Leo; Muriel Moser
Journal:  J Exp Med       Date:  2003-07-21       Impact factor: 14.307

10.  A controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  David H Miller; Omar A Khan; William A Sheremata; Lance D Blumhardt; George P A Rice; Michele A Libonati; Allison J Willmer-Hulme; Catherine M Dalton; Katherine A Miszkiel; Paul W O'Connor
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245

View more
  16 in total

1.  CD8-predominant T-cell CNS infiltration accompanies GVHD in primates and is improved with immunoprophylaxis.

Authors:  Saravanan Kaliyaperumal; Benjamin Watkins; Prachi Sharma; Scott Furlan; Swetha Ramakrishnan; Cynthia Giver; Anapatricia Garcia; Cynthia Courtney; Heather Knight; Elizabeth Strobert; Eric Elder; Timothy Crenshaw; Bruce R Blazar; Edmund K Waller; Susan Westmoreland; Leslie S Kean
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

2.  Leukotoxin kills rodent WBC by targeting leukocyte function associated antigen 1.

Authors:  Kristina M DiFranco; Rajesh H Kaswala; Chandni Patel; Chinnaswam Kasinathan; Scott C Kachlany
Journal:  Comp Med       Date:  2013-08       Impact factor: 0.982

3.  Sialomucin CD43 regulates T helper type 17 cell intercellular adhesion molecule 1 dependent adhesion, apical migration and transendothelial migration.

Authors:  Francisco E Velázquez; Marina Anastasiou; Francisco J Carrillo-Salinas; Njabulo Ngwenyama; Ane M Salvador; Tania Nevers; Pilar Alcaide
Journal:  Immunology       Date:  2019-02-17       Impact factor: 7.397

4.  Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis.

Authors:  Harald F Langer; Eun Young Choi; Hong Zhou; Rebecca Schleicher; Kyoung-Jin Chung; Zhongshu Tang; Kerstin Göbel; Khalil Bdeir; Antonios Chatzigeorgiou; Connie Wong; Sumeena Bhatia; Michael J Kruhlak; John W Rose; James B Burns; Kenneth E Hill; Hongchang Qu; Yongqing Zhang; Elin Lehrmann; Kevin G Becker; Yunmei Wang; Daniel I Simon; Bernhard Nieswandt; John D Lambris; Xuri Li; Sven G Meuth; Paul Kubes; Triantafyllos Chavakis
Journal:  Circ Res       Date:  2012-03-27       Impact factor: 17.367

5.  Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b.

Authors:  Chaofeng Han; Jing Jin; Sheng Xu; Haibo Liu; Nan Li; Xuetao Cao
Journal:  Nat Immunol       Date:  2010-07-18       Impact factor: 25.606

6.  ICAM-1null C57BL/6 Mice Are Not Protected from Experimental Ischemic Stroke.

Authors:  Gaby U Enzmann; Sofia Pavlidou; Markus Vaas; Jan Klohs; Britta Engelhardt
Journal:  Transl Stroke Res       Date:  2018-02-04       Impact factor: 6.829

7.  Expression of a single ICAM-1 isoform on T cells is sufficient for development of experimental autoimmune encephalomyelitis.

Authors:  Daniel C Bullard; Xianzhen Hu; David Crawford; Kristin McDonald; Theresa N Ramos; Scott R Barnum
Journal:  Eur J Immunol       Date:  2014-02-11       Impact factor: 5.532

8.  Discovery of novel disease-specific and membrane-associated candidate markers in a mouse model of multiple sclerosis.

Authors:  Laura F Dagley; Nathan P Croft; Ruth Isserlin; Jonathan B Olsen; Vincent Fong; Andrew Emili; Anthony W Purcell
Journal:  Mol Cell Proteomics       Date:  2013-12-20       Impact factor: 5.911

9.  Deletion of the complement phagocytic receptors CR3 and CR4 does not alter susceptibility to experimental cerebral malaria.

Authors:  T N Ramos; D C Bullard; S R Barnum
Journal:  Parasite Immunol       Date:  2012-11       Impact factor: 2.280

10.  Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE.

Authors:  Veit Rothhammer; Sylvia Heink; Franziska Petermann; Rajneesh Srivastava; Malte C Claussen; Bernhard Hemmer; Thomas Korn
Journal:  J Exp Med       Date:  2011-10-24       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.